Table 1.
NAC prevents HEMA mediated decrease in VEGF secretion in DPSCs and UCLA-2 cells:
| VEGF (pg/ml) | ||
|---|---|---|
| Human DPSCs | UCLA -2 | |
| Control | 2263.9± 5.71 | 3195.7± 25.99 |
| HEMA (0.0164M) | 113.4± 17.1* | 180.2± 57.09* |
| HEMA (0.0082M) | 125.1± 8.24* | 319.6± 6.34* |
| HEMA (0.00164M) | 163.7± 3.8* | 3258.8± 15.89 |
| NAC | 1804.1± 18.04 | 2831.9± 70.37 |
| NAC +HEMA (0.0164M) | 1060.4± 12.04** | 1773.8± 90.02** |
| NAC + HEMA (0.0082M) | 1719.0± 6.34** | 2024.3± 31.7** |
| NAC + HEMA (0.00164M) | 2490.6± 46.91** | 3352.0± 18.38 |
Human DPSCs (2.5×105/ml) cultured with the combination of β-glycerophosphate (10 mM) and ascorbic acid (50μg/ml), and UCLA-2 (2.5×105/ml) oral tumors were treated with varying concentrations of HEMA as indicated in the table and NAC (20 mM), and after an overnight incubation the supernatants were removed and assayed for VEGF secretion using a sensitive and specific ELISA. One of three independent experiments is shown in this table. Results represent mean±sd of triplicates. Based on one way ANOVA
p ≤0.001 and
p≤0.001 was obtained for the differences between HEMA treated and untreated cells, and between NAC+HEMA treated cells and HEMA alone treated cells at the respective concentrations for human DPSCs and UCLA-2 cells.